linjc16/ctgov huggingface dataset:
Prognostic Value of CTC in HNSCC Patients

Study Overview
=================
Brief Summary
-----------------
We hypothesized that the number of circulating tumor cells (CTCs) and molecular markers on CTCs could be a prognostic factor or predictive factor to patients with head neck cancer.

Detailed Description
-----------------
Histologically or cytopathologically proven head and neck squamous cell carcinoma (HNSCC) Disease status: locally advanced or recurrent/metastasized at initial presentation Age >=20 years old Could understand and signed the informed consents of this study Enrolled patients were classified into three distinct subgroups: Patients underwent curative surgery followed by adjuvant chemoradiotherapy (CRT) because of some pathologic features such as positive margin, pathologic N2, and extracapsular spread (ECS) of involved lymph nodes indicating early relapse according to recommendation from National Comprehensive Cancer Network(NCCN) guidelines; Patients with advanced disease directly underwent definitive concurrent chemoradiotherapy(CCRT); Patients were to have palliative chemotherapy for existence of distant metastasis or poor general condition for definitive CCRT. Blood samples were collected within 7 days before the first dose of chemotherapy.

Official Title
-----------------
Prognostic Value of Circulating Tumor Cells in Patients With Locally Advanced and Metastatic/Recurrent Head and Neck Cancer

Conditions
-----------------
Recurrence, Metastasis, Death

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: histologically or cytopathologically proven head and neck squamous cell carcinoma Age ≥ 20 years. Measurable or evaluable disease according to Response Evaluation Criteria In Solid Tumors(RECIST) criteria. Ability to sign informed consent. Exclusion Criteria: Prior cancers within 5 years, except for non-melanoma skin cancers, and in situ cervical cancers. Inability to comply with study and/or follow-up procedures.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival | Measure response or progression events via all available imaging studies, including Chest-Xray, CT scans, or MRI, PET study. The relationship between CTCs number and time from CTCs checkpoint to disease progression will be analyzed. | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Circulating tumor cells, Head and neck cancer, Squamous cell carcinoma, Survival, Prognosis
CardioRoot Post-Marketing Surveillance Registry

Study Overview
=================
Brief Summary
-----------------
Post-marketing surveillance registry of the CardioRoot graft.

Detailed Description
-----------------
Study objective is to monitor the performance and safety of CardioRoot vascular grafts implanted in a thoracic position. Patient survival rates will be monitored as well as immediate and long-term complications.

Official Title
-----------------
CardioRoot Post-Marketing Surveillance Registry

Conditions
-----------------
Cardiovascular Surgical Procedure

Intervention / Treatment
-----------------
* Device: CardioRoot graft


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients requiring a CardioRoot graft as per the CardioRoot Instructions for Use (IFU) Exclusion Criteria: patients with contra-indications per CardioRoot IFU patients requiring consecutive aortic surgery patients with coronary artery disease patients who require urgent or emergent surgery
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CardioRoot<br>All subjects receive the CardioRoot graft at baseline implant procedure. | Device: CardioRoot graft<br>* prospective single arm multi-center study to evaluate CardioRoot grafts implanted in a thoracic position.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Graft complications | Complications will be assessed out to one year post implantation. | 30 days | 
| Graft complications | Complications will be assessed out to one year post implantation. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subject mortality rate | Subject mortality rate will be followed out to one year post implantation. | 30 days, 1 year |
Surgical and Medical Emergencies on Board of European Aircraft Carriers

Study Overview
=================
Brief Summary
-----------------
The goal of this retrospective study is to describe emergency relevant illnesses occurring in airline passengers.

Detailed Description
-----------------
An epidemiologic database documenting medical and surgical emergencies across European airlines will provide access to data potentially valuable for further flight-epidemiological research. Data on medical emergencies / per rpk (revenue passenger kilometres) are sparse and often based on data from a single airline. While handling the data the regulations of the data protection act of the Ethic commission of the Ruhr-University Bochum are fully respected. As noted, evaluation of the data will be completely anonymized without any information regarding the airline or other details than the passengers illness. Preview: The results of the study specified above will be submitted for publication in a peer review and Medline listed journal. Study Design: Retrospective, epidemiological study for the evaluation of medical and surgical emergencies on board airliners. Patients: In the context of a retrospective study approximately 20,000 patient data from 32 European airlines are collected and statistically evaluated. Documentation: The direct documentation takes place through project responsible person into an electronic statistical data base.

Official Title
-----------------
Surgical and Medical Emergencies on Board of European Aircraft Carriers

Conditions
-----------------
Circulatory Collapse, Chest Pain, Diarrhea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men, women, adolescent, children and babies who have suffered from an emergency on board an European airline. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>The group includes 10189 patients with on board medical or surgical emergencies. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All cause mortality, cause of medical or surgical emergency while on aircraft |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
in-flight emergency
Modifiable Factors and Glaucoma - RCT

Study Overview
=================
Brief Summary
-----------------
There is growing awareness that environmental factors, behaviors and diet are intimately related to patient health and may play a role in the pathogenesis and progression of glaucoma. Evidence from recent years has shown that some behaviors and environmental factors can affect the intraocular pressure, the primary risk factor for glaucoma. This study aims to investigate whether simple and common lifestyle inteventions such as sleeping with a head elevation, a high fiber diet, moderate aerobic exercise and moderation in caffeine intake could affect intraocular pressure and other outcomes.

Official Title
-----------------
Modifiable Factors in the Management of Glaucoma - a Randomized Controlled Trial

Conditions
-----------------
Intraocular Pressure

Intervention / Treatment
-----------------
* Behavioral: Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with glaucoma. Exclusion Criteria: Not able to attend follow-up Contraindication for treatment or follow-up

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br>Recommendations for lifestyle changes which have shown to reduce IOP. recommendations include: Moderate aerobic exercise, High fiber diet, sleeping with a head elevation and moderating caffeine intake. while continuing prescribed medical therapy. | Behavioral: Intervention<br>* Recommendations for lifestyle changes which have shown to reduce IOP. recommendations include: Moderate aerobic exercise, High fiber diet, sleeping with a head elevation and moderating caffeine intake. while continuing prescribed medical therapy.<br>|
| No Intervention: Control<br>No intervention. patients are instructed to continue prescribed medical therapy. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraocular pressure |  | Following 1 month of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Illness perception questionnaire results |  | Following 1 month of treatment |
Central Venous Pressure (CVP) Assessment by Ultrasound and Physical Examination

Study Overview
=================
Brief Summary
-----------------
Ultrasound may be useful for noninvasively determining the central venous pressure. We intend to compare the clinical examination of the neck veins; ultrasound delineation of the internal jugular vein; and the central venous pressure measured with an intravascular catheter.

Official Title
-----------------
Use of Ultrasound to Determine Central Venous Pressure in Critically Ill Patients

Conditions
-----------------
Central Venous Pressure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult medical or surgical ICU patients who have preexisting central venous (jugular/subclavian only) catheters. Exclusion Criteria: subjects with only a femoral venous catheter. subjects whose CVP measurement by the indwelling catheter exceeds 20cm of water. subjects younger than 18 years old. inability to obtain informed consent from the subject or the subjects authorized representative.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of CVP measurement via ultrasound and central venous catheter | CVP as determined non-invasively with the transcutaneous ultrasound probe will correlate with a high degree of accuracy to the measurement obtained invasively by the catheter and pressure transducer. | At data collection: this is a physiologic study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of CVP measurement via physical examination of IJV and EJV. | Despite its more tortuous course and smaller caliber, the external jugular vein will be as reliable (compared to the catheter) as the internal jugular to estimate CVP | At data collection: physiologic study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CVP, US, Ultrasonography
TME Neoadjuvant Breast Registry

Study Overview
=================
Brief Summary
-----------------
Prospective observational registry that links results of the genomic and other molecular testing to treatment response and survival measures in patients who have been diagnosed with breast cancer and who are targeted for neo-adjuvant therapy. Analysis includes how tests impact treatment decisions and outcomes.

Detailed Description
-----------------
Physicians will order tests on patients as part of standard of care; they will report whether test results influenced: selection between standard therapies or a clinical trial; offered insight into mid therapy treatment changes; or helped physicians determine what therapy to offer patients who do not have a complete pathologic response. Patient demographics, diagnosis, type of treatment, surgery and pathologic results will be recorded. Patients will be followed for 5 years. Recurrence and survival data will be recorded. Participating sites will submit de-identified patient data via electronic case report forms (eCRFs) into a secure study website. All patients are required to sign an Informed Consent Form. All investigators and staff will have Human Subject Protection Training.

Official Title
-----------------
TME Neoadjuvant Breast Registry (The NEAT Registry)

Conditions
-----------------
Breast Cancer, Breast Neoplasms

Intervention / Treatment
-----------------
* Other: Genomic and/or molecular testing of blood or tissue


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with histologically proven invasive breast cancer who have started or are scheduled to start neo-adjuvant chemotherapy or endocrine therapy Ages 18-90 Written informed consent Exclusion Criteria: Patients who have had excisional biopsy or axillary dissection Patients with confirmed metastatic disease Patients who have had recent chemotherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Genomic and/or molecular testing of blood or tissue|Genomic and/or molecular testing of blood or tissue|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pathologic response and/or endocrine sensitivity |  | Post surgical treatment--usually within 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Metastasis-free/relapse-free survival in molecular subgroups |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast Cancer, Neoadjuvant therapy for breast cancer
Pediatric Hip Plate Versus Cannulated Screw in Pediatric Femoral Neck Fracture

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the early postoperative radiologic and clinical outcomes of pediatric hip plate and cannulated screw fixation in pediatric femoral neck fracture (Delbet type II and Delbet type III).

Detailed Description
-----------------
The children aged 3 to 14 years with femoral neck fracture that were treated with pediatric hip plate and cannulated screw fixation.

Official Title
-----------------
An Multicenter Prospective Observational Study to Pediatric Hip Plate Versus Cannulated Screw in Pediatric Femoral Neck Fracture (Delbet Type II and III)

Conditions
-----------------
Femoral Neck Fractures

Intervention / Treatment
-----------------
* Procedure: Pediatric hip plate
* Procedure: Cannulated screw


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with fractures that met these criteria, underwent definitive surgery and had complete clinical and radiographic follow up until fracture union at either institution were included in this study. Exclusion Criteria: Pathologic fractures, and fractures in patients with osteogenesis imperfecta, neuromuscular disorders or any systemic disease that was associated with a predisposition to fractures or altered fracture healing were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pediatric hip plate<br>The children were treated with pediatric hip plate. | Procedure: Pediatric hip plate<br>* Children were treated with pediatric hip plate.<br>|
| Cannulated screw<br>The children were treated with cannulated screw. | Procedure: Cannulated screw<br>* Children were treated with cannulated screw.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Radiographic union | The time of radiographic union. | Through study completion, an average of 0.5 year. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Ratliff classification standard score | Ratliff classification standard score was administered to determine the pain, function, activity and radiographic change. | Through study completion, an average of 1 year. |
Adoptive Immunotherapy for CMV Disease

Study Overview
=================
Brief Summary
-----------------
Treatment strategy of patients: Stem cell engraftment (myeloablative or NST) for induction of host vs graft myeloablative transplantation tolerance. Whenever indicated, additional post NST DLI given in graded increment, to optimize control of GVHD. Preparation of immune donor lymphocytes, either by donor immunization in-vitro with a CMV-specific peptide followed by administration of immunized donor lymphocytes, or by injection of donor lymphocytes and in-vivo sensitization of donor lymphocytes in the patient following DLI. Pre-emptive treatment of seronegative patients at risk or patients with documented viremia or CMV disease with CMV-specific donor lymphocytes generated in-vivo in the donor or in the host by peptide immunization. Consenting donors will be immunized with CMV-specific peptides, for induction of CTLs in-vivo following subcutaneous inoculation of peptides with adjuvant or donor APC pulsed with relevant peptides.

Official Title
-----------------
Prevention and Treatment of CMV Disease by Adoptive Immunotherapy With Immune Donor Lymphocytes in Conjunction With Non-myeloablative Stem Cell Transplantation (NST)

Conditions
-----------------
CMV Disease

Intervention / Treatment
-----------------
* Biological: CMV vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: For Patient: Consenting patients with indication for myeloablative BMT or NST with an HLA matching sibling available, for transplant. Patients at risk of CMV disease including seronegative patients; patients with seronegative donors, and seronegative donor for sero positive patients. Patients with resistant CMV viremia or CMV disease not responding to conventional treatment with ganciclovir, or Foscarnet. Patients with HLA phenotype for which a relevant peptide for CMV exists. For Donor: Consenting sibling >18 years old. HLA phenotype for which a relevant peptide for CMV exists. Exclusion Criteria: For Patient: Patients with severe resistant GVHD where there may be a risk to administer DLI or immunized donor lymphocytes. For Donor: Consenting sibling >18 years old. HLA phenotype for which a relevant peptide for CMV exists. Donor with an infectious disease (e.g. HIV-1; HBV, etc.)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: CMV vaccine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Induce and amplify T cell-mediated immunotherapy against cytomegalovirus (CMV) infection in stem cell allograft recipients. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate toxicity of the procedure. |  |  |